Related Experiment Video
Updated: Sep 3, 2026
Anti-Nuclear Antibody Screening Using HEp-2 Cells
Published on: June 24, 2014
MPO-ANCA necrotizing glomerulonephritis related to rheumatoid arthritis
T Messiaen1, P M'bappé, J J Boffa
1Department of Nephrology, Tenon Hospital, Paris, France.
Abstract:
Two patients with rheumatoid arthritis (RA) developed necrotizing crescentic glomerulonephritis with high titers of anti-myeloperoxidase antibodies (MPO) in the absence of overt extrarenal vasculitis. We therefore suggest that in some patients with RA, MPO-ANCA necrotizing glomerulonephritis (GN) may occur as a kidney-limited form of rheumatoid vasculitis, and that RA should be added to the list of diseases potentially associated with necrotizing GN with anti-MPO antibodies. These observations also point out the importance of repeatedly evaluating titers of anti-MPO antibodies in the course of RA, especially if renal impairment or abnormal urinary sediment are present.
Insights
Rheumatoid arthritis (RA) patients can develop kidney-only vasculitis, specifically anti-myeloperoxidase (MPO) necrotizing glomerulonephritis (GN). Monitoring MPO antibody titers is crucial for early detection in RA patients with kidney issues.
Area of Science:
- Nephrology
- Rheumatology
- Immunology
Background:
- Rheumatoid arthritis (RA) is a systemic autoimmune disease.
- Vasculitis can affect various organs, including the kidneys.
- Anti-myeloperoxidase (MPO) antibodies are associated with certain forms of glomerulonephritis.
Observation:
- Two patients with RA presented with necrotizing crescentic glomerulonephritis (GN).
- These patients exhibited high titers of anti-MPO antibodies.
- No overt signs of systemic or extrarenal vasculitis were observed in these cases.
Findings:
- The cases suggest MPO-ANCA-associated necrotizing GN can occur as a kidney-limited manifestation of rheumatoid vasculitis in RA patients.
- Rheumatoid arthritis should be considered a potential underlying condition for necrotizing GN with anti-MPO antibodies.
Implications:
- This highlights the importance of considering rheumatoid vasculitis in RA patients presenting with glomerulonephritis.
- Regular monitoring of anti-MPO antibody titers is recommended for RA patients with renal impairment or abnormal urinary findings.
- Early detection and management of MPO-ANCA GN in RA may improve renal outcomes.
